EurekAlert! -
1 Jan 2019 07:00
(University of Kentucky) In an editorial in CNS Spectrums, a neurologists takes the research community to task for its lack of minority representation in Phase III clinical trials for drugs to treat Multiple Sclerosis (MS) and proposes changes to the system.
Share this Article
Comment on this Article
Please to comment